Precigen

Company Snapshot

Founded: 1998
Entity Type: Public
Employees: 47
Region: U.S.
Revenue: $9.7 Millions
Revenue Year: 2025
Headquarter: Maryland, U.S.
Key Geographics: North America
Corporate Address: 20358 Seneca Meadows Parkway Germantown Maryland 20876 U.S. Tel. +1-301-556-9900 www.precigen.com

Company Overview

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases.

In 2015, Intrexon purchased Oxitec, a maker of gene drive technology for $160 million. In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Company's Business Segments

  • Biopharmaceuticals : This segment comprises the company's legal entities, Precigen and ActoBio, and royalty interests in therapeutics and therapeutic platforms from companies not controlled by it.
  • Exemplar : This segment includes Exemplar Genetics LLC, doing business as Precigen Exemplar, or Exemplar, our wholly owned subsidiary, focused on developing research models and services for healthcare research applications.

Applications/End User Industries

  • Biopharmaceutical
  • Healthcare
  • Life Sciences
AI Sentiment